Share on StockTwits

Shares of Bristol-Myers Squibb (NYSE:BMY) have earned an average recommendation of “Hold” from the eighteen ratings firms that are currently covering the company, AR Network reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $51.83.

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $49.89, for a total value of $997,800.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Bristol-Myers Squibb (NYSE:BMY) opened at 50.22 on Thursday. Bristol-Myers Squibb has a 52 week low of $41.32 and a 52 week high of $57.49. The stock’s 50-day moving average is $49.49 and its 200-day moving average is $50.45. The company has a market cap of $83.260 billion and a P/E ratio of 31.21.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 24th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company’s quarterly revenue was down 3.9% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday. They noted that the move was a valuation call. Separately, analysts at Deutsche Bank initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday. They set a “hold” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.